In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.
first published: Jul 21, 2011 03:55 pm
A collection of the most-viewed Moneycontrol videos.

India–US Trade Deal Is Here! Markets Explode, Rupee Soars | What Changes Now?

Live: Sensex, Nifty jumps 2% on India-US deal optimism, Rupees firms up | Closing Bell

India-US Trade Deal Set To Ignite The Bulls| GIFT NIFTY Signals 1000+ Point Gap Up | Opening Bell Live

Exclusive Post-Budget Interview: FM Sitharaman in Conversation with Rahul Joshi
You are already a Moneycontrol Pro user.